Special Issue "Personalized Prevention of Gallbladder Cancer"

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: 25 August 2022 | Viewed by 2753

Special Issue Editors

Prof. Dr. Justo Lorenzo Bermejo
E-Mail Website
Guest Editor
Statistical Genetics Research Group, Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
Interests: Statistics for Molecular Medicine; Personalized Prevention; Gallbladder Cancer; Risk Biomarkers
Dr. Dominique Scherer
E-Mail Website
Guest Editor
Statistical Genetics Research Group, Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
Interests: Personalized Prevention; Gallbladder Cancer; Genetics; Risk Biomarkers

Special Issue Information

Dear Colleagues,

Gallbladder cancer (GBC, ICD-10 diagnosis code C23) is an aggressive malignancy that accounts for the majority of biliary tract tumours, especially in low- and middle-income countries. Resection of tumours confined to the mucosa is currently the only potentially curative treatment, but early diagnosis is difficult because early symptoms are inconspicuous and nonspecific. On the other hand, GBC develops over a long period of time and surgical removal of the gallbladder in individuals at high-risk of GBC or affected by pre-neoplastic lesions offers a good opportunity for personalized GBC prevention.

This Special Issue of the Journal of Personalized Medicine aims to highlight the current status and recent developments in the broad field of personalized GBC prevention. Articles on the identification and characterization of novel risk and early disease biomarkers, on the causal mechanisms linking lifestyle, culture and behaviour to GBC development, and on novel opportunities for targeted therapy of incidental tumours are particularly welcome.

Prof. Dr. Justo Lorenzo Bermejo
Dr. Dominique Scherer
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gallbladder cancer
  • personalized prevention
  • risk biomarker
  • primary prevention
  • secondary prevention/early detection
  • tertiary prevention/avoidance of gallbladder cancer progression

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Article
Validation of an NGS Panel Designed for Detection of Actionable Mutations in Tumors Common in Latin America
J. Pers. Med. 2021, 11(9), 899; https://doi.org/10.3390/jpm11090899 - 08 Sep 2021
Viewed by 1262
Abstract
Next-generation sequencing (NGS) is progressively being used in clinical practice. However, several barriers preclude using this technology for precision oncology in most Latin American countries. To overcome some of these barriers, we have designed a 25-gene panel that contains predictive biomarkers for most [...] Read more.
Next-generation sequencing (NGS) is progressively being used in clinical practice. However, several barriers preclude using this technology for precision oncology in most Latin American countries. To overcome some of these barriers, we have designed a 25-gene panel that contains predictive biomarkers for most current and near-future available therapies in Chile and Latin America. Library preparation was optimized to account for low DNA integrity observed in formalin-fixed paraffin-embedded tissue. The workflow includes an automated bioinformatic pipeline that accounts for the underrepresentation of Latin Americans in genome databases. The panel detected small insertions, deletions, and single nucleotide variants down to allelic frequencies of 0.05 with high sensitivity, specificity, and reproducibility. The workflow was validated in 272 clinical samples from several solid tumor types, including gallbladder (GBC). More than 50 biomarkers were detected in these samples, mainly in BRCA1/2, KRAS, and PIK3CA genes. In GBC, biomarkers for PARP, EGFR, PIK3CA, mTOR, and Hedgehog signaling inhibitors were found. Thus, this small NGS panel is an accurate and sensitive method that may constitute a more cost-efficient alternative to multiple non-NGS assays and costly, large NGS panels. This kind of streamlined assay with automated bioinformatics analysis may facilitate the implementation of precision medicine in Latin America. Full article
(This article belongs to the Special Issue Personalized Prevention of Gallbladder Cancer)
Show Figures

Figure 1

Review

Jump to: Research

Review
Environmental and Lifestyle Risk Factors in the Carcinogenesis of Gallbladder Cancer
J. Pers. Med. 2022, 12(2), 234; https://doi.org/10.3390/jpm12020234 - 08 Feb 2022
Viewed by 720
Abstract
Gallbladder cancer (GBC) is an aggressive neoplasm that in an early stage is generally asymptomatic and, in most cases, is diagnosed in advanced stages with a very low life expectancy because there is no curative treatment. Therefore, understanding the early carcinogenic mechanisms of [...] Read more.
Gallbladder cancer (GBC) is an aggressive neoplasm that in an early stage is generally asymptomatic and, in most cases, is diagnosed in advanced stages with a very low life expectancy because there is no curative treatment. Therefore, understanding the early carcinogenic mechanisms of this pathology is crucial to proposing preventive strategies for this cancer. The main risk factor is the presence of gallstones, which are associated with some environmental factors such as a sedentary lifestyle and a high-fat diet. Other risk factors such as autoimmune disorders and bacterial, parasitic and fungal infections have also been described. All these factors can generate a long-term inflammatory state characterized by the persistent activation of the immune system, the frequent release of pro-inflammatory cytokines, and the constant production of reactive oxygen species that result in a chronic damage/repair cycle, subsequently inducing the loss of the normal architecture of the gallbladder mucosa that leads to the development of GBC. This review addresses how the different risk factors could promote a chronic inflammatory state essential to the development of gallbladder carcinogenesis, which will make it possible to define some strategies such as anti-inflammatory drugs or public health proposals in the prevention of GBC. Full article
(This article belongs to the Special Issue Personalized Prevention of Gallbladder Cancer)
Show Figures

Figure 1

Back to TopTop